|
Hepatitis B Research Network (HBRN)
|
Research Initiative
|
CDC
|
NIDDK, NCI
|
The Hepatitis B Research Network (HBRN), supported by NIDDK, was established in 2008 to advance understanding of disease processes and natural history of chronic hepatitis B, as well as to develop effective approaches to treatment with currently available therapies. The Network brought together clinical centers from throughout the US and Canada. This multi-center Network enrolled patients in multiple clinical trials in both adults and children with hepatitis B. The Network is currently completing and publishing analyses from these trials.
|
|
HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis Interagency Implementation Group (VHIG)
|
Research Initiative
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIDA, NIAID, NIDDK, NIMHD
|
The Department of Health and Human Services (HHS) agencies review the Institute of Medicine (IOM) recommendations and develop a comprehensive strategic viral hepatitis action plan that would: address IOM recommendations for viral hepatitis prevention, care, and treatment; set forth actions to improve viral hepatitis prevention and ensure that infected persons are identified and provided care and treatment; and improve coordination of all activities related to viral hepatitis across HHS and promote collaborations with other government agencies and nongovernmental organizations.
|
|
HHS Adolescent Health Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA
|
NIDA, NIAAA, NICHD, NIMH
|
This interagency working group, which was established in January 2010 within the Office of the Assistant Secretary for Health, provides a forum for Department of Health and Human Services (HHS) agencies and other federal agencies to learn from each other and support a full-range of evidence-based approaches to improve adolescent health, to address adolescents’ health risks, and highlight programs focused on positive youth development. This collaboration among many HHS agencies and offices serves as a forum for exchanging information relevant to improving adolescent health and well-being.
|
|
HHS Adult Maltreatment Prevention Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, CDC, CMS, HRSA, IHS, OS, SAMHSA
|
NIA
|
To discuss department-wide interests and priorities.
|
|
HHS Agency Priority Goal on Equity Workgroup (FY 2022-2023)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, ASPE, CDC, CMS, HRSA
|
NIMHD, OD/OEDI, NICHD
|
The goal of the Agency Priority Goal (APG) Workgroup was to investigate the feasibility of developing the Equity priority area into a viable APG. The workgroup was charged with identifying ongoing activities that align to this priority area and contain components of an APG, and if feasible, developing a draft Impact Statement for submission to HHS leadership and OMB. Agency Priority Goals (APGs) focus the attention of leadership and contributing agencies on achieving critical performance goals for the Department. APGs are required by the Government Performance and Results Act Modernization Act of 2010 (GPRAMA).
|
|
HHS Antiretroviral Treatment Guidelines Panel for Adults and Adolescents with HIV
|
Committee, Work group, Advisory group, or Task Force
|
HRSA, CDC, FDA
|
NIAID
|
The Panel was formed in 1996, to provide guidelines for clinicians for adult and adolescents with HIV. The Panel is a working group of the NIH Office of AIDS Research Council. One of the co-chairs of the Panel is Dr. Cliff Lane of NIAID, the executive secretary is Alice Pau of NIAID. The Panel updates the guidelines annually, and more frequently if needed.
|
|
HHS Behavioral Health Coordinating Council (BHCC) Overdose Prevention Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA, OASH, ASPE
|
NIDA, OD/OSP
|
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; determining the public health impact of kratom scheduling; and improving clinician education on controlled substance prescribing.
|
|
HHS Behavioral Health Coordinating Council, Subcommittee on Children and Youth
|
Committee, Work group, Advisory group, or Task Force
|
HRSA, SAMHSA, FDA, OASH, CMS
|
NICHD, NIMH, NIDA
|
Overall, the BHCC is intended to inform the department-wide behavioral health agenda and provide recommendations on agency priorities and strategic planning.
|
|
HHS Biannual Dual Use Research of Concern (DURC) Inventory
|
Resource Development
|
CDC, FDA, OS
|
OD/OSP, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI
|
Develops the Department of Health and Human Services (HHS) Biannual Dual Use Research of Concern (DURC) inventory reports, as required by the United States Government (USG) Policy for Oversight of Dual Use Research of Concern.
|
|
HHS Biosafety and Biosecurity Coordinating Council (HHS BBCC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, OD/ORS
|
High-level and formal mechanism for coordinating and collaborating on biosafety and biosecurity issues across the Department of Health and Human Services.
|